Australian Pharmaceutical Industries Limited (API)

Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

Sign Up Today » it's FREE! Already a member? Login now!

General Information
Company Name: Australian Pharmaceutical Industries Limited
Stock Code: API
GICS Sub-Industry: Health Care Distributors
Market Cap ($M): 420
Equiv. Shares (M): 488

Current Price Data+
Current Price Open High Low Last Close Volume Price Movement
 $ 0.835 $ 0.845 $ 0.850 $ 0.835 $ 0.860 270,698 $ -0.025  -2.907 %

Current Broker Consensus Recommendation more
Recommendation: Buy (2)
Recommendation Date: 26th Nov 2014
Brokers Surveyed: 2

Company Overview

Business Description:
Australian Pharmaceutical Industries Limited (API) is an Australian health and beauty services company. API provides wholesale product delivery services, retail services, marketing programs and business advisory services to customers. API also has as a number of brands and banners in the retail health and beauty industry, including Priceline, Soul Pattinson and Pharmacist Advice. API has three main businesses namely, Pharmacy Distribution, Manufacturing and Retail.

Strategy Analysis:
Under the 'Revitalise' plan, a new network plan is forecasted to reduce $18m in annualised cost over 3 years. Total required investment for the program is approximately $60m. Goals include: combining two supply chains into a single system to reduce inventory and freight costs; increase automation at distribution centres; and IT improvements. Revitalise program to consolidate Supply Chain is expected to deliver savings in FY11 of $10m and $18m in FY12. In its retail operations, management is looking to transfer further Priceline corporate stores to franchises. API will also focus is on organic growth in pharmacy and retail operations, as well as improving cost efficiencies.. Australian Pharmaceutical Industries reported NPAT of $30.28m for the year ended 31 August 2012. Revenue from ordinary activities were $3.22bn, down 6.1% from last year. Basic and Diluted EPS were 6.2 cents compared to (4.8) cents last year. Net operating cash flow was $47.82m compared to $48.21m last year. The final dividend declared was 1.5 cents, taking the full year dividend to 3 cents compared with 2.5 cents last year.

Financial Summary
Year to Aug NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2016  F -- 7.7 7.4 11.1 4.4 5.1 --
2015  F -- 7.2 -- 11.9 3.7 4.3 --
2014  A -110.9 -22.7 -- 0.0 3.5 6.2 100.0
Source: Aspect actuals / Thomson IBES estimates

Peer Comparison
EPS Growth (%) P/E (%) Dividend Yield (%)
Company Mkt Cap 2014 A 2015 F 2016 F 2014 A 2015 F 2016 F 2014 A 2015 F 2016 F
Australian Pharmaceutical Industries (API) $430 M -- -- 0.0736 -- 12.2222 11.3842 3.98 4.16 5.02
Primary Health Care (PRY) $2,335 M 0.0787 0.0994 0.0811 14.1615 12.8814 11.9153 4.39 4.67 5.06
Sonic Healthcare (SHL) $6,880 M 0.1328 0.0692 0.1098 17.9581 16.7956 15.1341 3.91 4.15 4.61
Sigma Pharma. (SIP) $837 M -0.2237 0.0764 0.1704 16.4847 15.3144 13.0849 5.30 2.65 6.11

Market Comparison
Earnings P/E Ratio P/B Ratio P/E Growth P/S Ratio
API 0.70 -- 0.87 -- 0.13
Market 0.92 15.3 1.20 1.77 1.54
Sector 0.66 18.7 2.41 1.66 2.05

Name Position Start Date
Mr Stephen Patrick Roche Chief Executive Officer,Managing Director 14 August 2006
Mr Robert Dobson Millner Non-Executive Director 12 May 2000
Ms Esther Carol Holley Non-Executive Director 19 December 2006
Mr Gerard James Masters Non-Executive Director 07 September 2010
Mr Kenneth William Gunderson-Briggs Non-Executive Director 06 May 2014
Dr Michael Wooldridge Non-Executive Director 01 February 2006
Ms Lee Ausburn Non-Executive Director 07 October 2008
Mr Peter Raymond Robinson Non-Executive Director,Non-Executive Chairman 05 May 2000

Name Position
Genevieve Ryan Alternate Company Secretary
Graeme Fallet Chief Financial Officer
Peter F Sanguinetti Company Secretary
Stephen Arthurson General Manager, People
Richard Vincent Group General Manager, Business Development & Operations

Substantial Shareholders
Holding Name
32,138,866 (6.58%) Citicorp Nominees Pty Limited
120,214,969 (24.63%) Washington H Soul Pattinson and Co Ltd
58,122,597 (11.91%) S L Nominees Pty Ltd and Associates
31,110,561 (6.37%) J P Morgan Nominees Australia Limited
29,809,565 (6.11%) HSBC Custody Nominees (Australia) Limited

Calendar of Events
Date Event
22 October 2015 Report (Prelim)
29 April 2015 Report (Interim)
12 December 2014 AGM
12 December 2014 Div Pay Date
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at


Trade Shares Online from $19.95^
Free Guides

The SMH Guide to Investing in Shares via SMSFs

An educational booklet that outlines how to get the most from your share investments for retirement thorugh your self managed super fund.

More details...


Australian Share Market - Close Up

CMC Markets 11/11/2014 | The Australian share market is in a decision zone - and trading from here may set the direction for the rest of the year.

Prices slashed - everything must go!

Nick Swales, Regional Director, Newcastle Office, Rathbones 27/10/2014 | “If you want to have a better performance than the crowd, you must do things differently from the crowd.” Sir John Templeton.

Aussie share market bulls now have company

Ric Spooner (Chief Market Analyst, CMC Markets) 20/10/2014 | Today, Australian investors will not have to go it alone buying stocks as they did for much of last week. Bargain hunters this morning will be supported by the morale boosting encouragement of a 3% turnaround in the German Dax and a 264 point rally in the Dow Jones.

The Importance of Ignoring the Noise of the Market

Carl Richards, director of investor education at the BAM Alliance 17/10/2014 | “As odd as it may sound, the sooner you start treating your investments like you treat life, the happier you’ll be with the outcome.”

You only dance twice

William H. Gross, Janus Capital Group 16/10/2014 | “Financial markets are artificially priced. In the bond market, there is nothing normal about a three year German Bund yielding “minus” 10 basis points.”

The Big Picture - Australia 200 Index

CMC Markets 8/10/2014 | Share market indices around the globe are breaking down. While analysts cast around for reasons, it’s clear that a time factor is in play. Simply put, many investors “feel” a correction is overdue. How low could it go?


Sponsored Links